Last reviewed · How we verify
NCT03541148
Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma
Phase 2 trial testing Oncoxin-Viusid in Cutaneous Melanoma, Stage II in 20 participants. Completed in 13 April 2018.
13 April 2016
Quick facts
| Lead sponsor | Catalysis SL |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 20 |
| Start date | 16 September 2014 |
| Primary completion | 13 April 2016 |
| Estimated completion | 13 April 2018 |
| Sites | 1 location across Cuba |
Drugs / interventions tested
- Oncoxin-Viusid
Conditions studied
- Cutaneous Melanoma, Stage II — all drugs for Cutaneous Melanoma, Stage II →
- Malignant Cutaneous Melanoma — all drugs for Malignant Cutaneous Melanoma →
- Cutaneous Melanoma, Stage III — all drugs for Cutaneous Melanoma, Stage III →
Sponsor
Catalysis SL — full company profile →
Who can join
18 and older, any sex, with Cutaneous Melanoma, Stage II or Malignant Cutaneous Melanoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Malignant melanoma, responsible for 75% of deaths from skin cancer. Current therapeutic options have poor response, many adverse events and high costs. For this reason, a study with nutritional supplement Oncoxin-Viusid was carried out. According to previous studies, it has an antitumor, immunomodulatory effect and to potentiate the antiproliferative effect of standard chemotherapeutic agents in different locations and stages of cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03541148
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Oncoxin-Viusid
Trials testing the same drug.
- NCT03543670 — Evaluation of Oncoxin-Viusid® in Prostate Cancer · Phase 2 · completed
Other recruiting trials for Cutaneous Melanoma, Stage II
Currently open trials in the same condition.
- NCT03860883 — Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma · NA · recruiting
Other Catalysis SL trials
Trials by the same sponsor.
- NCT07179237 — Efficacy of Carminal in Helicobacter Pylori Gastritis · Phase 2 · recruiting
- NCT06363201 — Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumour · NA · not yet recruiting
- NCT05916911 — Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In P · Phase 4 · unknown
- NCT06496087 — Evaluation of DEPREXIL in Patients With Clinical Depression Through Psychological and Neuroendocrine Assessment · NA · completed
- NCT06361992 — Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03541148 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Catalysis SL
- Last refreshed: 30 May 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03541148.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing